Menin Inhibitor
FDA Approves Syndax’s First-in-Class Menin Inhibitor with Black-Box Warning; Updates on GSK’s ADC Deal
Syndax; Revuforj; revumenib; FDA approval; menin inhibitor; black-box warning; acute leukemia; KMT2A translocation; differentiation syndrome; acute myeloid leukemia (AML); GSK; antibody-drug conjugate (ADC); oncology drug approval
Fierce Biotech Fundraising Tracker ’25: CHARM attracts $80M; Wugen reels in $115M
CHARM Therapeutics; AI drug design; menin inhibitor; acute myeloid leukemia (AML); Series B funding; venture capital; biotech fundraising; Wugen; NVIDIA; drug development
Kura Oncology’s Ziftomenib Achieves Phase 2 Success in AML, Paving Way for Dual-Track Phase 3 Program
Ziftomenib, Acute Myeloid Leukemia (AML), NPM1 mutation, KMT2A rearrangement, Phase 3 trials, KOMET-001, KOMET-017, Menin inhibitor, Breakthrough Therapy Designation
FDA Approves Revuforj, a First-in-Class Menin Inhibitor, for Relapsed or Refractory Acute Leukemia with KMT2A Translocation
FDA approval, Revuforj, Menin inhibitor, Acute leukemia, KMT2A translocation, Relapsed or refractory, Syndax Pharmaceuticals